OMX:IMMU

Immunicum AB (publ) Stock Insider Trading

Stockholm Stock Exchange > Healthcare > Biotechnology

kr9.14

+0.230 (+2.58%)

At Close: Jun 20, 2024

Immunicum AB (publ) Stock Insider Power

Based on the 0 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 0 and sold 0 IMMU.ST shares in the last 0 trades.

Historical Insider Trades

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

Sorry! Image not available at this moment

About Immunicum AB (publ)

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid... IMMU.ST Profile

Golden Star

Ticker	Date	Change	Price
V	Jun 18	0.585%	$273.62
EPD	Jun 18	0.95%	$28.30
USFD	Jun 18	0.565%	$53.14
RGA	Jun 17	1.62%	$203.90
MA	Jun 17	1.50%	$448.11
BR	Jun 17	1.59%	$197.65
^DJI	Jun 17	0.92%	38,778.10 points
SARK	Jun 17	1.85%	$30.34
DRI	Jun 14	3.02%	$148.78
BXSL	Jun 14	1.56%	$31.33

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Sign In